HC
RXRX icon

Hurley Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

Hurley Capital’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.61K Hold
850
– – ﹤0.01% 546
2025
Q4 		$3.48K Buy
+850
New +$4.21K ﹤0.01% 477

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Hurley Capital's RXRX Position: Q1 2026 in Review

Hurley Capital held its Recursion Pharmaceuticals (RXRX) position steady in Q1 2026 at 850 shares worth $2.61K. The position accounts for ﹤0.01% of the portfolio, ranked #546.

Hurley Capital first reported a position in RXRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $3.48K in Q4 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Hurley Capital held 850 shares of Recursion Pharmaceuticals worth $2.61K as of Q1 2026.
  • Hurley Capital left its Recursion Pharmaceuticals share count unchanged in Q1 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Hurley Capital's portfolio in Q1 2026, its #546 holding.
  • Hurley Capital first reported a position in Recursion Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Hurley Capital's Recursion Pharmaceuticals position peaked at $3.48K in Q4 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Hurley Capital's 13F filing for Q1 2026, filed 6 May 2026.